No­var­tis' San­doz chief is walk­ing out in the mid­dle of a glob­al re­vamp, fu­el­ing fresh buzz about a spin­off

The head of No­var­tis’ big gener­ics di­vi­sion San­doz has abrupt­ly hand­ed in his walk­ing pa­pers in a move that will im­me­di­ate­ly reignite spec­u­la­tion that CEO Vas Narasimhan may be prep­ping a spin­off plan for the strug­gling group as the par­ent or­ga­ni­za­tion con­cen­trates on de­vel­op­ing new drugs.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER